Main content

    Pancreatic Clinical Research

    Adult Clinical Trials Main Page

    CPMC Cancer Services

    Principal Investigator/Contact InformationProtocol TitlePatient Population Recruitment Period
    Principal Investigator:
    CPMC Oncologists

    Contact:
    Brenda Eng
    415-600-1775
    Email engb@cpmcri.org    		A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC-718781) + IMC-A12 (NSC-742460) + Gemcitabine + Erlotinib as 1st Line Treatment in Patients with Metastatic Pancreatic Cancer (SWOG 0727)
    Visit the Metastatic Pancreatic Cancer study on ClinicalTrials.gov.    		Patients with pancreatic cancer that has spread to other parts of your body.Open
    Principal Investigator:
    Ari Baron, MD

    Contact:
    Anna Ruiz
    415-600-3214
    Email ruizac@cpmcri.org    		A Phase II Study of Hyperacute®-Pancreatic Cancer Vaccine in subjects with surgically resected Pancreatic Cancer. NewLink Genetics NLG0205
    Visit the Pancreatic Cancer Vaccine study on ClinicalTrials.gov.    		Subjects with Pancreatic Cancer Open



    updated: 4/1/2010


    Back to top